DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Eganelisib
Eganelisib
PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects
Immunotherapy in Adrenocortical Carcinoma: Predictors of Response, Efficacy, Safety, and Mechanisms of Resistance
353 Safety and Efficacy of Tumor Infiltrating Lymphocytes (TIL, LN-145
Perspectives in Immunotherapy: Meeting Report from the Immunotherapy Bridge (December 2Nd–3Rd, 2020, Italy) Paolo A
Immunotherapy in the Treatment of Lymphoma
Standard of Care and Promising New Agents for the Treatment of Mesenchymal Triple-Negative Breast Cancer
Standard of Care and Promising New Agents for the Treatment of Mesenchymal Triple-Negative Breast Cancer
INFINITY PHARMACEUTICALS, INC. Form 8-K Current Event Report
Phosphoinositide 3-Kinase
PI3K/Akt/Mtor
Arcus Biosciences Announces Third Quarter 2020 Financial Results and Corporate Updates
2020 Medicines in Development ꟷ Cancer
Anti-COVID-19 Compound Library (96-Well)
PI3K/Akt Pathway: the Indestructible Role of a Vintage Target As a Support to the Most Recent Immunotherapeutic Approaches
Bioactive Compound Library Plus (96-Well)
Eganelisib First‐In‐Class PI3K‐ Inhibitor Targeting Immune Suppressive Myeloid Cells in Metastatic Triple‐Negative Breast Cancer
Targeting PI3K/AKT/Mtor Signaling Pathway in Breast Cancer
Drug Repurposing Compound Library Plus (96-Well)
Top View
Our Vision: Combining to Cure with Best-In-Class Cancer Therapies
Anti-Aging Compound Library (96-Well)
Targeting the PI3K/AKT/Mtor Pathway in Epithelial Ovarian Cancer, Therapeutic Treatment Options for Platinum-Resistant Ovarian Cancer
Drug Repurposing Compound Library (96-Well)
Cytoskeleton Compound Library (96-Well)
Urothelial Carcinoma
The E Cacy of Pi3kγ and EGFR Inhibitors on the Suppression of The
352 Updated Clinical Data from The